• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Nexalin Technology, Inc. - Common Stock (NQ: NXL )

    4.220 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Nexalin Technology, Inc. - Common Stock

    < Previous 1 2 Next >
    Nexalin Technology CEO Provides Letter to Shareholders
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on November 5th
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    LOBO EV and Nexalin Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Nexalin Technology Announces Landmark Study on Alzheimer's Disease and Deep Intracranial Frequency Stimulation Published in Journal of Alzheimer's Disease
    New Data Confirms DIFS Improves Cognitive Function and Restores Brain Activity in Alzheimer's Patients 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    NASDAQ Stocks Under $1 to Watch in October 2024: LGCB, KAVL, NXL, NXU, FAMI
    Via AB Newswire
    Topics Economy Electric Vehicles
    Exposures Electric Vehicles Supply Chain
    Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
    Groundbreaking Trial Reveals DIFS Increases Neural Activity and Blood Flow in the Hippocampus, Offering Hope for Alzheimer’s Treatment 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
    Veteran medical device executive to drive regulatory and clinical strategy as Nexalin advances drug-free Deep Intracranial Frequency Stimulation (DIFS) technology for mental health treatment 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
    Meeting showcases the potential role of Nexalin's neurostimulation technology in revolutionizing opioid treatment through virtual care solutions 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Closing of $5.2 Million Public Offering
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Pricing of $5.2 Million Public Offering
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device for the Treatment of Alzheimer’s and Dementia
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESSWIRE
    Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)
    Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    MicroCap Rodeo’s Spring into Summer Conference, June 6th 2024 - 25 Presenting Companies
    Via ACCESSWIRE
    Nexalin Technology to Present at the Spring MicroCap Rodeo Conference on June 6th
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
    Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device
    New method of use patent covers key aspects of the technology that enable patients to receive treatment from the privacy of their own homes 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board
    Previously served as Acting General Counsel to the Department of Veterans Affairs 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology
    Mental Health Center Initially Focused on Treatment of Patients with Substance Abuse Disorder 
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    Nexalin Technology Announces Poster Presentation at “State of the Technology Meeting: Neurotrauma Diagnosis, Monitoring, and Assessment”
    From Nexalin Technology, Inc.
    Via GlobeNewswire
    < Previous 1 2 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.